The novel ss469415590 variant predicts virological response to therapy in patients with chronic hepatitis C virus type 1 infection

Alimentary Pharmacology and Therapeutics

Volumn 39, Issue 3, 2014, Pages 322-330

  Covolo, L ^a   Bibert, S ^b   Donato, F ^a   Bochud, P Y ^b   Lagging, M ^c   Negro, F ^d   Fattovich, G ^e  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d University Hospital   (Switzerland)

^e UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ALLELE; AREA UNDER THE CURVE; ARTICLE; CAUCASIAN; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DRUG CONTRAINDICATION; FEMALE; GENE; GENE ACTIVATION; GENE FUNCTION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; IL28B GENE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NONHUMAN; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT RESPONSE; VIRAL CLEARANCE;

ADULT; ANTIVIRAL AGENTS; CHEMOKINE CXCL10; COHORT STUDIES; DRUG THERAPY, COMBINATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84891882651     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12568     Document Type: Article

References (33)

1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST,. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-42.
2. Sarrazin C, Hézode C, Zeuzem S, Pawlotsky JM,. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012; 56 (Suppl. 1): S88-100.
3. Rangnekar AS, Fontana RJ,. Meta-analysis: IL28B genotype and sustained viral clearance in HCV genotype 1 patients. Aliment Pharmacol Ther 2012; 36: 104-14.
4. Gane EJ, Roberts SK, Stedman CA, et al,. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010; 376: 1467-75.
5. Chu TW, Kulkarni R, Gane EJ, et al,. Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. Gastroenterology 2012; 142: 790-5.
6. Zeuzem S, Soriano V, Asselah T, et al,. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med 2013; 369: 630-9.
7. Urban TJ, Thompson AJ, Bradrick SS, et al,. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010; 52: 1888-96.
8. Bibert S, Roger T, Calandra T, et al,. IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J Exp Med 2013; 210: 1109-16.
9. Prokunina-Olsson L, Muchmore B, Tang W, et al,. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 2013; 45: 164-71.
10. Askarieh G, Alsiö A, Pugnale P, et al,. Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. Hepatology 2010; 51: 1523-30.
11. Fattovich G, Covolo L, Bibert S, et al,. IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. Aliment Pharmacol Ther 2011; 33: 1162-72.
12. Bedossa P, Poynard T,. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-93.
13. Ghany MG, Strader DB, Thomas DL, Seeff LB,. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
14. Rauch A, Kutalik Z, Descombes P, et al,. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-45.
15. Pepe MS,. The Statistical Evaluation of Medical Tests for Classification and Prediction. Oxford: Oxford University Press, 2003.
16. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS,. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157-72.
17. Kramer B, Nischalke HD, Boesecke C, et al,. Variation in IFNL4 genotype and response to interferon-based therapy of hepatitis C in HIV-positive patients with acute and chronic hepatitis C. AIDS 2013; 27: 2817-9.
18. Franco S, Aparicio E, Parera M, et al,. IFNL4 ss469415590 variant is a better predictor than ILF3 (IL28B) rs12979860 of pegylated interferon-alpha/ ribavirin therapy failure in hepatitis C virus/HIV-1 coinfected patients. AIDS 2013; PMID: 24072198 [Epub ahead of print].
19. Lagging M, Askarieh G, Negro F, et al,. Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS ONE 2011; 6: e17232.
20. Bochud P-Y, Bibert S, Kutalik Z, et al,. IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology 2012; 55: 384-94.
21. Rembeck K, Westin J, Lindh M, et al,. Association between interleukin-28B-related genetic variants and liver histopathology differs between hepatitis C virus genotypes. Hepatology 2012; 56: 394.
22. Suppiah V, Moldovan M, Ahlenstiel G, et al,. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat Genet 2009; 41: 1100-4.
23. Tanaka Y, Nishida N, Sugiyama M, et al,. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-9.
24. Honda M, Sakai A, Yamashita T, et al,. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010; 139: 499-509.
25. Dill MT, Duong FH, Vogt JE, et al,. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 2011; 140: 1021-31.
26. Booth D, George J,. Loss of function of the new interferon IFN-λ4 may confer protection from hepatitis C. Nat Genet 2013; 45: 119-20.
27. McGilvray I, Feld JJ, Chen L, et al,. Hepatic cell-type specific gene expression better predicts HCV treatment outcome than IL28B genotype. Gastroenterology 2012; 142: 1122-31.
28. Romero AI, Lagging M, Westin J, et al,. Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis 2006; 194: 895-903.
29. Lagging M, Romero AI, Westin J, et al,. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology 2006; 44: 1617-25.
30. Jia Z, Ding Y, Tian S, Niu J, Jiang J,. Test of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: results from a meta-analysis. PLoS ONE 2012; 7: e45698.
31. Jiménez-Sousa MA, Fernández-Rodríguez A, Guzmán-Fulgencio M, García-Álvarez M, Resino S,. Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C. BMC Med 2013; 11: 6.
32. Andriulli A, Di Marco V, Marcaglione M, et al,. Identification of naive HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin. J Hepatol 2014; 60: 16-21.
33. Holmes JA, Desmond PV, Thompson AJ,. Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection? J Viral Hepat 2012; 19: 677-84.